News
PEPG
12.49
+4.69%
0.56
Weekly Report: what happened at PEPG last week (0422-0426)?
Weekly Report · 7h ago
New Strong Buy Stocks for April 25th
NASDAQ · 4d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 6d ago
Weekly Report: what happened at PEPG last week (0415-0419)?
Weekly Report · 04/22 09:03
PepGen Inc.'s (NASDAQ:PEPG) market cap dropped US$79m last week; individual investors who hold 48% were hit as were institutions
Simply Wall St · 04/20 12:09
Weekly Report: what happened at PEPG last week (0408-0412)?
Weekly Report · 04/15 09:03
12 Health Care Stocks Moving In Friday's Pre-Market Session
PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. Allarity Therapeutics stock increased by 55.84% and HCW Biologics shares increased by 20.77%. Losers Motus GI Hldgs stock fell 26.1% during the session.
Benzinga · 04/12 12:09
Insiders Buying GameStop And 2 Other Stocks
U.S. Stocks closed mixed on Tuesday. There were a few notable insider trades. GameStop Corp. And PepGen Inc. Made notable insider purchases. Tile Shop Holdings, Inc. Also made a notable purchase. Insider purchases indicate confidence in the company's prospects or a bargain.
Benzinga · 04/10 12:11
Weekly Report: what happened at PEPG last week (0401-0405)?
Weekly Report · 04/08 09:03
Weekly Report: what happened at PEPG last week (0325-0329)?
Weekly Report · 04/01 09:03
Weekly Report: what happened at PEPG last week (0318-0322)?
Weekly Report · 03/25 09:03
Weekly Report: what happened at PEPG last week (0311-0315)?
Weekly Report · 03/18 09:03
PepGen to Participate in Upcoming Investor Conferences
PepGen Inc. Management will participate in the following upcoming investor conferences. PepGen is a clinical-stage biotechnology company advancing the treatment of severe neuromuscular and neurological diseases. The company will be attending the following investor conferences:  
Barchart · 03/13 15:05
PepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51
NASDAQ · 03/13 12:05
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations
PepGen has received the FDA's orphan drug and rare pediatric disease designations for its experimental therapy for Duchenne muscular dystrophy patients. PGN-EDO51 received the designations to treat the rare genetic disorder. The company is assessing the experimental therapy in the ongoing Phase 2 trial.
Dow Jones · 03/13 11:27
3 Best Stocks to Buy Now, 3/12/2024, According to Top Analysts
TipRanks · 03/12 10:09
Stifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)
TipRanks · 03/12 02:15
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 03/11 16:00
Weekly Report: what happened at PEPG last week (0304-0308)?
Weekly Report · 03/11 09:03
3 Best Stocks to Buy Now, 3/8/2024, According to Top Analysts 
TipRanks · 03/08 07:05
More
Webull provides a variety of real-time PEPG stock news. You can receive the latest news about PepGen Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEPG
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.